NVE (NVEC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Definitive additional proxy materials filed, indicating updates or supplemental information for shareholders.
No filing fee required for this submission, suggesting routine or informational content.
Voting matters and shareholder proposals
Proxy materials are being provided to shareholders, likely in advance of an upcoming meeting for voting purposes.
Notice of Internet Availability issued, indicating shareholders can access proxy materials online.
Shareholder rights and capital structure
Shareholders are notified of the availability of proxy materials, supporting transparency and access to information.
Partial view of Summaries dataset, powered by Quartr API
Latest events from NVE
- Quarterly revenue rose 23% and net income 11% year-over-year, with a $1.00 dividend declared.NVEC
Q3 20263 Feb 2026 - Revenue and net income declined, but gross margin and cash returns to shareholders remained strong.NVECQ1 20253 Feb 2026
- Gross margin rose to 86% as R&D revenue surged and a $1.00 dividend was declared.NVECQ2 202519 Jan 2026
- Revenue and net income fell, but gross margin improved to 84% and a dividend was declared.NVECQ3 20259 Jan 2026
- Maintained strong earnings, expanded R&D, and appointed a new director with medical expertise.NVECProxy Filing1 Dec 2025
- Annual meeting to elect directors, approve pay, and ratify auditor, with focus on ESG and governance.NVECProxy Filing1 Dec 2025
- Key votes on directors, executive pay, and auditor ratification, with strong governance and ESG focus.NVECProxy Filing1 Dec 2025
- Annual Meeting to vote on directors, executive pay, and auditor ratification August 1, 2024.NVECProxy Filing1 Dec 2025
- Strong earnings, R&D investment, and 39% shareholder return highlight a year of innovation and growth.NVECProxy Filing1 Dec 2025